BDP1 and ovarian serous adenocarcinoma: At twelve‐month relapse‐free survival, in patients treated with platin, BDP1 expression significantly decreased (p = 0.0014), and the ROC analysis (p = 7.6 × 10−05, AUC = 0.663) (Figure 5A) suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer.